Neuphoria Therapeutics

(NASDAQ) NEUP

Current Price$4.76

Market Cap$8.84M

Since IPO (2024)-29%

5 YearN/A

1 Year-31%

1 Month-11%

Neuphoria Therapeutics Financials at a Glance

Market Cap

$8.84M

Revenue (TTM)

-$10.47M

Net Income (TTM)

-$27.55M

EPS (TTM)

-$23.89

P/E Ratio

-0.20

Dividend

$0.00

Beta (Volatility)

0.64 (Low)

Dividend

$0.00

Beta (Volatility)

0.64 (Low)

Price

$4.76

Volume

Open

$4.76

Price

$4.76

Volume

Open

$4.76

Previous Close

$4.70

Daily Range

$4.76 - $4.76

52-Week Range

$3.65 - $21.40

Dividend

$0.00

Beta (Volatility)

0.64 (Low)

Price

$4.76

Volume

Open

$4.76

Previous Close

$4.70

Daily Range

$4.76 - $4.76

52-Week Range

$3.65 - $21.40

NEUP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Neuphoria Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Spyridon Papapetropoulos, MD, PhD

Website

www.neuphoriatx.com

Headquarters

Burlington, US

NEUP Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

Return on Capital

-79%

Return on Assets

-79%

Earnings Yield

-5.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$8.84M

Shares Outstanding

1.88M

Volume

Avg. Volume

53.18K

Financials (TTM)

Gross Profit

$15.65M

Operating Income

-$1.13M

EBITDA

-$121.90K

Operating Cash Flow

$77.23M

Capital Expenditure

$0.00

Free Cash Flow

$77.23M

Cash & ST Invst.

$21.59M

Total Debt

$226.49K

Neuphoria Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$165.70K

-100.7%

Gross Margin

0.00%

N/A

Market Cap

$8.84M

N/A

Market Cap/Employee

$1.10M

N/A

Employees

N/A

Net Income

-$505.06K

-102.7%

EBITDA

-$1.00M

-105.0%

Quarterly Fundamentals

Name

Q3 2026YOY CHG

Net Cash

$19.41M

+15.0%

Accounts Receivable

$1.61M

+6427.9%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$34.23K

-77.7%

Return on Assets

-79.16%

N/A

Return on Invested Capital

-78.65%

N/A

Free Cash Flow

-$3.87M

-133.8%

Operating Cash Flow

-$3.87M

-133.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CHEKCheck-Cap Ltd.

CHEKCheck-Cap Ltd.$1.86+1.64%

BMRABiomerica, Inc.

BMRABiomerica, Inc.$2.06-2.37%

LFWDLifeward Ltd.

LFWDLifeward Ltd.$7.15-1.79%

BCDABioCardia, Inc.

BCDABioCardia, Inc.$0.89+1.61%

APREAprea Therapeutics, Inc.

APREAprea Therapeutics, Inc.$0.75-1.47%

PTHLPheton Holdings Ltd Class A Ordinary Shares

PTHLPheton Holdings Ltd Class A Ordinary Shares$0.28-5.73%

LUCYInnovative Eyewear, Inc.

LUCYInnovative Eyewear, Inc.$0.96-0.52%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$37.19+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$86.56-0.01%

NOWLGraniteShares ETF Trust - GraniteShares 2x Long Now Daily ETF

NOWLGraniteShares ETF Trust - GraniteShares 2x Long Now Daily ETF$6.42-0.15%

BBBlackBerry

BBBlackBerry$10.18-0.01%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$36.25-0.02%

NOKNokia

NOKNokia$15.62-0.07%

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF$13.49-0.01%

Questions About NEUP

What is the current price of Neuphoria Therapeutics?

Neuphoria Therapeutics is trading at $4.76 per share.

What is the 52-week range for Neuphoria Therapeutics?

Over the past 52 weeks, Neuphoria Therapeutics has traded between $3.65 and $21.40.

How much debt does Neuphoria Therapeutics have?

As of the most recent reporting period, Neuphoria Therapeutics reported total debt of $34.23K.

How much cash does Neuphoria Therapeutics have on hand?

Neuphoria Therapeutics reported $19.44M in cash and cash equivalents in its most recent financial results.

What is Neuphoria Therapeutics’s dividend yield?

Neuphoria Therapeutics does not currently have a dividend yield.

Neuphoria Therapeutics

Neuphoria Therapeutics Financials at a Glance

NEUP News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Neuphoria Therapeutics

NEUP Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Neuphoria Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NEUP

What is the current price of Neuphoria Therapeutics?

What is the 52-week range for Neuphoria Therapeutics?

How much debt does Neuphoria Therapeutics have?

How much cash does Neuphoria Therapeutics have on hand?

What is Neuphoria Therapeutics’s dividend yield?

Premium Investing Services